Dudley MP Ian Austin is supporting an inquiry into access to treatment as part of the All-Party Parliamentary Group on Haemophilia.
People with genetic bleeding disorders lack certain proteins that enable their blood to clot normally. They require replacement clotting factors or other therapies to manage their bleeding.
However, new longer lasting treatments are available that can improve ease of use, allow patients to be more active, provide better protection from bleeds and reduce the occurrence of joint damage in the longer term.
New treatments for bleeding disorders including gene therapy and other novel therapies are expected to be licensed over the coming years, but there are concerns that the commission processes restrict access to new developments.
Ian Austin said:
“It’s crucial that patients with haemophilia get the safest and easiest treatment available.
“That’s why I’m supporting the call for evidence for future treatments of Haemophilia and Contaminated Blood.”